Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zenocutuzumab by Merus for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...
Zenocutuzumab by Merus for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive...
Zenocutuzumab by Merus for Non-Small Cell Lung Cancer: Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Pre-Registration for Non-Small Cell Lung Cancer. According to GlobalData, Pre-Registration...
Zenocutuzumab by Merus for Metastatic Breast Cancer: Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase...
Zenocutuzumab by Merus for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Pre-Registration for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Pre-Registration drugs...
Risk adjusted net present value: What is the current valuation of Merus's Zenocutuzumab?
Zenocutuzumab is a monoclonal antibody commercialized by Merus, with a leading Pre-Registration program in Pancreatic Ductal Adenocarcinoma. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Merus's Zenocutuzumab?
Zenocutuzumab is a monoclonal antibody commercialized by Merus, with a leading Pre-Registration program in Non-Small Cell Lung Cancer. According to...